Laddar populära aktier...
Redeye provides a research update following Lipum’s clinical progress, recent rights issue, and revi...
XVIVO improved its organic growth to 32% compared with the unusually modest 12% level in Q4 2023.
Redeye leaves a comment following the yesterday’s press release of the preliminary outcome of Lipum’...
Scanfil’s Q1 results were expected to be soft relative to the comparison period but still came in so...
Spain's largest grocery retailer commits to StrongPoint Large market potential - EUR 250m in spain a...
Redeye expected higher sales in the quarter. Particularly from Coating Services where revenues are t...
Organic growth of 79%, +34pp above ABGSCe Paying users 6% above ABGSCe Likely positive cons.
Net sales and EBIT were below consensus (LSEG) in Q1.
Strong growth, only slightly below our high expectations -4.
Redeye provides its initial take on Lifco’s Q1 2024 report, which came in broadly below our estimate...
Redeye comments on Evolution’s Q1-results which were slightly ahead of our forecasts although EBITDA...
Net sales SEK 572m, 3% vs ABGSCe EBITA SEK 84m, 7% vs ABGSCe Thebalux performs well at 25% EBITA mar...
Redeye initiates coverage of Oncopeptides, a commercial-stage biotech company focusing on multiple m...
Atria's Q1 EBIT came in clearly above LSEG Data & Analytics consensus despite the ongoing ramp-up of...
Drop in sales due to tough comps Gross margin negatively impacted by mix effects EBITDA revised down...